In a second arm of the ISPY-2 trial, neoadjuvant durvalumab and olaparib in combination with paclitaxel (DOP) were compared to paclitaxel alone in patients with high risk, HER2- breast cancer (52 HR+ and 21 TNBC), regardless of BRCA status (166). Here, ERBB2 is linked to breast cancer.